Christoph Rader, Ph.D.
Advisor since 2022
“RiverVest’s strong scientific foundation, especially in the field of immunology, really impresses me. This foundation is a big reason why I believe that in collaborating with the RiverVest team, we can help innovative therapies reach their full potential to improve and save lives.”
Dr. Christoph Rader is a Professor in the Department of Immunology and Microbiology, formerly at The Scripps Research Institute in Jupiter, FL (TSRI-FL), which was integrated into The University of Florida (UF) in 2022. Dr. Rader’s research focuses on the development and application of technologies for antibody drug and target discovery in cancer, with an emphasis on technologies at the interface of biology and chemistry.
Dr. Rader’s contributions in the field of antibody discovery and development are many. In addition to 150 peer-reviewed publications, Dr. Rader is named inventor on 20 issued and numerous pending U.S. patents along with a large international patent portfolio. Several antibodies developed in his laboratories have been licensed to companies and translated to clinical trials. In addition, he has served for 10 years as an NIH reviewer of small business grants and consulted widely in the American and European pharma, biotech, and venture capital industries. In 2017, he co-founded the CAR-T company T-CURX (Würzburg, Germany). From 2013-2021, he served on the Scientific Advisory Board (SAB) of NBE-Therapeutics (Basel, Switzerland) until its acquisition by Boehringer Ingelheim. Currently he is a member of the SAB of Pyxis Oncology (Cambridge, MA).
Dr. Rader studied biochemistry in Germany and Switzerland where he received his Ph.D. from the University of Zurich in 1995. Following postdoctoral training at The Scripps Research Institute in La Jolla, CA (TSRI-CA), he was appointed Assistant Professor at TSRI-CA in 1999. In 2003, he was recruited as Senior Scientist to the National Cancer Institute, National Institutes of Health in Bethesda, MD (NCI, NIH) where he served as Head of the Antibody Technology Section in the Experimental Transplantation and Immunology Branch, Center for Cancer Research. He joined TSRI-FL as Associate Professor with Tenure in 2012 and was promoted to Professor in 2019. From 2018 to 2022 he also served as Associate Dean of TSRI’s Skaggs Graduate School of Chemical and Biological Sciences.
Personal Interests: hiking, mountain biking, snowboarding and Formula One
St. Louis, San Diego & Cleveland
Collaborative Approach and Open Communication
An exceptional firm culture where each is expected to be transparent, strategic, dependable, results-driven, collaborative, and grounded in purpose. That's RiverVest.